CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK-IN-2
CAS:<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Fórmula:C18H19ClFN3O2Pureza:99.67%Forma y color:SolidPeso molecular:363.819-Isopropylolomoucine
CAS:<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Fórmula:C17H22N6OPureza:99.82%Forma y color:SolidPeso molecular:326.4CDK8-IN-1
CAS:<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Fórmula:C11H8F3N3OPureza:98.48%Forma y color:SolidPeso molecular:255.2Cdc7-IN-7c
CAS:<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Fórmula:C15H17N5OSPureza:98.19% - 99.22%Forma y color:SolidPeso molecular:315.39SEL120-34A
CAS:<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Fórmula:C15H18Br2N4Pureza:99.764% - 99.84%Forma y color:SolidPeso molecular:414.14CDK4/6/1 Inhibitor
CAS:<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Fórmula:C28H30F2N6Pureza:99.26% - 99.72%Forma y color:SolidPeso molecular:488.57BML-259
CAS:<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Fórmula:C14H16N2OSPureza:99.84%Forma y color:SolidPeso molecular:260.35dCeMM2
CAS:<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Fórmula:C16H11ClN6OSPureza:99.68%Forma y color:SolidPeso molecular:370.82Cdk2 Inhibitor II
CAS:<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Fórmula:C14H11BrN4O3SPureza:97.07%Forma y color:SolidPeso molecular:395.23Abemaciclib metabolite M20
CAS:<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。</p>Fórmula:C27H32F2N8OPureza:98.1% - 99.08%Forma y color:SolidPeso molecular:522.59SHP2/CDK4-IN-1
CAS:<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Fórmula:C33H35ClF2N10OSForma y color:SolidPeso molecular:693.21CDK-IN-11
CAS:<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Fórmula:C25H21BrN4O2Forma y color:SolidPeso molecular:489.36CDK/HDAC-IN-3
CAS:<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Fórmula:C24H18Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:509.34Cdk4 Inhibitor
CAS:<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Fórmula:C20H10BrN3O2Forma y color:SolidPeso molecular:404.2EHT 5372
CAS:<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Fórmula:C17H11Cl2N5OSForma y color:SolidPeso molecular:404.27Nε-(1-Carboxyethyl)-L-lysine
CAS:<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Fórmula:C9H18N2O4Forma y color:SolidPeso molecular:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Fórmula:C26H34N8OPureza:99%Forma y color:SolidPeso molecular:474.6CDK8-IN-3
CAS:<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Fórmula:C22H23N5O2Pureza:98%Forma y color:SolidPeso molecular:389.45CDK9-IN-29
CAS:<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Fórmula:C29H33F2N5O4Pureza:98%Forma y color:SolidPeso molecular:553.6IIIM-290
CAS:<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Fórmula:C23H21Cl2NO5Pureza:98%Forma y color:SolidPeso molecular:462.32
